European Society for Medical Oncology (ESMO)

Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation. Read More ›

Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies. Read More ›

Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients. Read More ›

Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers. Read More ›

Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors. Read More ›

Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer. Read More ›

Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer. Read More ›

This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer. Read More ›

Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo. Read More ›

Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established. Read More ›